bibliographic resource 2502645 [br/2502645]
https://w3id.org/oc/corpus/br/2502645
- is a
-
- title
-
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
- publication date
-
- contributor
-
- format
-
- identifier
-
- part of
-